Description Transforming Cancer Therapy Together At ADC Therapeutics, we are passionate about revolutionizing cancer treatment. When you join our team, you become part of a mission-driven group of talented individuals dedicated to making a difference in patients' lives. ADC Therapeutics ADC Therapeutics (NYSE): is a commercial, global leader and pioneer in the field of antibody-drug conjugates (ADCs) with specialized capabilities from clinical through commercialization. Our CD-19-directed ADC for relapsed/refractory non-Hodgkin lymphoma, ZYNLONTA® (loncastuxamab tesirine lpyl) has received accelerated approval in the United States and conditional approval from the European Commission.

ZYNLONTA

is also being evaluated in combination with other agents and in earlier lines of DLBCL therapy as well as in indolent lymphomas including follicular lymphoma and marginal zone lymphoma with the potential to reach significantly more patients through expanded use. We are a team of approximately 150 patient-focused, purpose-driven employees with a shared mission to transform the treatment paradigm for patients. If you're interested in making a difference in the lives of patients worldwide with a team of like-minded colleagues, operating in a flexible work environment, come join us on our journey! To learn more about ADC Therapeutics, our values, and our exceptional culture, please visit us at https://adctherapeutics.com/ and LinkedIn . The Senior Clinical Development Physician Contractor for the

ZYNLONTA

Program will work approximately 30-40 hours per week remotely (with a preference for New Jersey/East Coast based).

Key Responsibilities:

Medical Monitoring & Patient Safety Oversight —

ZYNLONTA

Program Serve as the medical monitor for

ZYNLONTA

studies providing real-time clinical judgment on eligibility, dose modifications, premedication compliance, and management of class-specific toxicities (e.g., effusions/edema, cutaneous reactions, hepatic abnormalities, hematologic toxicity). Perform detailed clinical data review of patient data profiles and other eCRF data (including drafting data queries, discussion of patient cases with Investigators, etc.) Lead ongoing benefit-risk assessment, including review of SAEs, AESIs (PBD-ADC class effects), and emerging safety signals; partner with Pharmacovigilance, DSMC/iDMC, and Biostatistics to ensure timely signal detection and risk mitigation. Cross-Functional Partner Partner with Translational Medicine, Biomarkers, and Biostatistics to characterize patient outcomes on

ZYNLONTA

(including by COO/GCB vs. non-GCB, double/triple-hit status, prior CAR-T exposure, and age/frailty), informing label strategy and lifecycle planning. Quality, Compliance & Inspection Readiness Ensure all medical monitoring and sBLA activities are conducted in compliance with

ICH-GCP, FDA/EMA

regulations, and internal SOPs; maintain audit- and inspection-ready documentation of clinical decisions and benefit-risk rationale in preparation for pre-approval inspections (BIMO) and sponsor inspections.

Requirements Minimum Qualifications:

MD required, MD/PhD preferred Board certification in Hematology/Oncology (in U.S. clinic preferred) Some clinical experience treating aggressive B-cell lymphomas (DLBCL, HGBCL, transformed FL) strongly preferred 15+ years of clinical R D experience in biopharma (or a combination of clinical and industry experience) Direct experience with antibody-drug conjugates (ADCs) — particularly PBD-based or CD19-targeted agents Familiarity with the evolving DLBCL treatment landscape and ability to position

ZYNLONTA

strategically within it. Join Our Inclusive Team ADC Therapeutics is proud to be an Affirmative Action/EEO Employer. EOE Minorities/Females/Protected Veterans/Disabled. We are committed to building diverse teams and fostering an inclusive, professional, and respectful work environment where employees are empowered for success.